A methodical up-titration schedule and clear expectations help patients reach the point where advanced therapy is appropriate. With no approved CIndU medication, clinicians are extrapolating from CSU.
Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit alongside nonsteroidal agents. Lawrence Eichenfield, MD ...
The US Food and Drug Administration (FDA) has approved pritelivir (HOVILPRI; Asahi Kasei Therapeutics) 100-mg tablets for the ...
Galderma announced an agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion, a move designed to expand ...
Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker ...
Remibrutinib is approved for chronic spontaneous urticaria (CSU) and most recently, symptomatic dermographism, with the label ...
In "Recognizing EPP: Diagnostic Red Flags, Psychosocial Burden, and Confirmatory Workup," Dr. Bonkovsky turns to what should ...
Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...
Adults with chronic hand eczema (CHE) treated within the Duke University Health System reported substantial work productivity ...
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about ...
In "Case 2: Escalating Therapy After Biologic Failure in HS," the panel shifts to the series' second patient case.
A patient with 45 percent hair loss and a wedding in six months illustrates why psychosocial burden can reclassify disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results